This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $50.94, moving -1.22% from the previous trading session.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck's (MRK) Pneumococcal Vaccine sBLA Faces FDA Delay
by Zacks Equity Research
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Novavax (NVAX) Seeks EU Nod for COVID-19 Vaccine in Kids
by Zacks Equity Research
Novavax (NVAX) seeks label expansion for its COVID-19 vaccine in adolescents aged 12-17 years in the European Union. Currently, the vaccine is authorized for use in adults.
Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS
by Kinjel Shah
FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.
J&J (JNJ) Gets FDA Nod for HIV Jab, Cabenuva, in Adolescents
by Zacks Equity Research
The FDA approves Johnson & Johnson's (JNJ) Cabenuva for treating HIV-1 in virologically suppressed adolescents aged 12 years and above.
FDA Authorizes Pfizer, Moderna's Second COVID Booster Dose
by Kinjel Shah
The FDA authorized a second booster dose of COVID-19 vaccines made by Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) for older adults and some immunocompromised individuals.
Pfizer (PFE) 2nd Ulcerative Colitis Study on Etrasimod Succeeds
by Zacks Equity Research
Pfizer's (PFE) ELEVATE UC 52 is the second phase III study on etrasimod for ulcerative colitis to have met primary and key secondary endpoints.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $52.74, moving -1.01% from the previous trading session.
FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy
by Zacks Equity Research
The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.
The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer
by Zacks Equity Research
Novartis, Merck and Pfizer have been included in this Analyst Blog.
Pfizer's (PFE) Etrasimod Meets Ulcerative Colitis Study Goals
by Zacks Equity Research
Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.
Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.
Pharma Stock Roundup: NVS, MRK Get FDA Nod, PFE Ulcerative Colitis Study Succeeds
by Kinjel Shah
FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis study on etrasimod meets goal.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $52.19, marking a -1.6% move from the previous day.
Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
Pfizer (PFE) Recalls Hypertension Drug Due to Impurities
by Zacks Equity Research
Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.
FDA Panel to Discuss Fourth Booster Dose in April Meeting
by Kinjel Shah
The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.
Moderna (MRNA) Up on FDA Filing for Second COVID Booster Jab
by Zacks Equity Research
Moderna (MRNA) seeks the FDA's authorization for a fourth dose of its COVID vaccine in adults who already got an initial authorized booster dose of the same in the United States.
The Zacks Analyst Blog Highlights J&J, Pfizer, BioNTech, and Moderna
by Zacks Equity Research
J&J, Pfizer, BioNTech, and Moderna have been highlighted in this Analyst Blog.
What's in Store for J&J's (JNJ) Segments & Pipeline in 2022?
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.
Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs
by Zacks Equity Research
With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.